[1]Ko J, Lee YH, Hwang SY, et al.Identification and differential ex-pression of novel human cervical cancer oncogene HCCR-2 in hu-man cancers and its involvement in p53 stabilization[J].Onco-gene, 2003, 22 (30) :4679-4689.
|
[2] Cho GW, Shin SM, Kim HK, et al. HCCR-1, a novel oncogene, encodes a mitochondrial outer membrane protein and suppresses the UVC-induced apoptosis[J]. BMC Cell Biol, 2007, 8: 50.
|
[3] Ha SA, Shin SM, Lee YJ, et al. HCCRBP-1 directly interacting with HCCR-1 induces tumorigenesis through p53 stabilization[J]. Int J Cancer, 2008, 122 (3) : 501-508.
|
[4]Shin SM, Chung YJ, Oh ST, et al.HCCR-1-interacting mole-cule“deleted in polyposis 1”plays a tumor-suppressor role in co-lon carcinogenesis[J].Gastroenterology, 2006, 130 (7) :2074-2086.
|
[5] Hurlstone A, Clevers H. T-cell factors: turn-ons and turn-offs[J]. EMBO J, 2002, 21 (10) : 2303-2311.
|
[6]Jia Y, Yang Y, Liu S, et al.SOX17 antagonizes WNT/beta-cate-nin signaling pathway in hepatocellular carcinoma[J].Epigenetics, 2010, 5 (8) :743-749.
|
[7] ShulewitzM, Soloviev I, Wu T, et al. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer[J]. Oncogene, 2006, 25 (31) : 4361-4369.
|
[8]Cho GW, Kim MH, Kim SH, et al.TCF/beta-catenin plays animportant role in HCCR-1 oncogene expression[J].BMC Mol Bi-ol, 2009, 10:42.
|
[9] Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1 /Par-4 axis: a cancer-selective therapeutic target[J]. Cancer Res, 2006, 66 (6) : 2889-2892.
|
[10] Cho GW, Shin SM, Namkoong H, et al. The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression[J]. Gene, 2006, 384: 18-26.
|
[11]Li CM, Narayanan R, Lu Y, et al.2-Arylthiazolidine-4-car-boxylic acid amides (ATCAA) target dual pathways in cancer cells:5'-AMP-activated protein kinase (AMPK) /mTOR and PI3K/Akt/mTOR pathways[J].Int J Oncol, 2010, 37 (4) :1023-1030.
|
[12] Chen J, Gomes AR, Monteiro LJ, et al. Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast Cancer[J]. PLoS One, 2010, 5 (8) : e12293.
|
[13]Xu Z, Zhang Y, Jiang JK, et al.Epidermal growth factor inducesHCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pan-creatic cancer cells[J].BMC Cancer, 2010, 10:161.
|
[14] Nagata Y, Takahashi A, Ohnishi K, et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status[J]. Int J Oncol, 2010, 37 (4) : 1001-1010.
|
[15]Le Mellay V, Troppmair J, Benz R, et al.Negative regulation ofmitochondrial VDAC channels by C-Raf kinase[J].BM Cell Bi-ol, 2002, 3 (1) :14.
|
[16] Lee HC, Li SH, Lin JC, et al. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma[J]. Mutat Res, 2004, 547 (1-2) : 71-78.
|
[17] Zotova L, Aleschko M, Sponder G, et al. Novel components of an active mitochondrial K (+) /H (+) exchange[J]. J Biol Chem, 2010, 285 (19) : 14399-14414.
|
[18] Beppu T, Gil-Bernabe P, Boveda-Ruiz D, et al. High incidence of tumors in diabetic thrombin activatable fibrinolysis inhibitor and apolipoprotein E double deficient mice J[J]. Thromb Haemost, 2010, 8 (11) : 2514-2522.
|
[19] Porrata-Doria T, Matta JL, Acevedo SF. Apolipoprotein E Allelic Frequency Altered in Women with Early-onset Breast Cancer[J]. Breast Cancer (Auckl) , 2010, 4: 43-48.
|
[20] Su WP, Chen YT, Lai WW, et al. Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer[J]. Lung Cancer, 2011, 71 (1) : 28-33.
|
[21] Ha SA, Shin SM, Kim HK, et al. Dual action of apolipoprotein E-interacting HCCR-1 oncoprotein and its implication for breast cancer and obesity[J]. J Cell Mol Med, 2009, 13 (9B) : 3868-3875.
|
[22]van der Pluijm G.Epithelial plasticity, cancer stem cells and bone me-tastasis formation[J].Bone, 2010, 48 (1) :37-43.
|
[23] Ha SA, Kim HK, Yoo J, et al. Transdifferentiation-inducing HCCR-1 oncogene[J]. BMC Cell Biol, 2010, 11: 49.
|
[24] Talos F, Moll UM. Role of the p53 family in stabilizing the genome and preventing polyploidization[J]. Adv Exp Med Biol, 2010, 676: 73-91.
|
[25] Bourdon JC. p53 and its isoforms in cancer[J]. Br J Cancer, 2007, 97 (3) : 277-282.
|
[26]Oh YT, Chun KH, Park BD, et al.Regulation of cyclin-depend-ent kinase inhibitorp21WAF1/CIP1 by protein kinase Cdelta-me-diated phosphorylation[J].Apoptosis, 2007, 12 (7) :1339-1347.
|
[27] Ko J, Shin SM, Oh YM, et al. Transgenicmousemodel for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice[J]. Oncogene, 2004, 23 (10) : 1950-1953.
|
[28]Ha SA, Lee YS, Shin SM, et al.Oncoprotein HCCR-1 expressionin breast cancer is well correlated with known breast cancer prognos-tic factors including the HER2 overexpression, p53 mutation, andER/PR status[J].BMC Cancer, 2009, 9:51.
|
[29]Yang Y, Zhou XF, Liu AD.The inhibition effect and its molecularmechanism of human cervical cancer oncogene siRNA on hepatocar-cinoma cells[J].Zhonghua Gan Zang Bing Za Zhi, 2008, 16 (8) :612-615.
|
[30]Yang Y, Zhang GX, Shi RH, et al.Overexpression of HCCR in hepa-tocellular carcinoma cells and its clinical significance[J].ZhonghuaGan Zang Bing Za Zhi, 2007, 15 (3) :223-224.
|
[31]Yoon SK, Lim NK, Ha SA, et al.The human cervical cancer onco-gene protein is a biomarker for human hepatocellular carcinoma[J].Cancer Res, 2004, 64 (15) :5434-5441.
|